Vaccine Development Challenges Include Extensive Quality Control, Sanofi's Loew Notes
Executive Summary
Sanofi spends 70% of vaccine production on quality control, Sanofi Pasteur exec VP David Loew tells the Pink Sheet; company is working on next generation flu vaccines that may provide greater efficacy.